ReviewCurrent opinion in immunology2011
Prevention of cancer by prophylactic human papillomavirus vaccines.
Review in Current opinion in immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- HPV-specific antibodies in female genital tract secretions captured via first-void urine retain their neutralizing capacity.Human vaccines & immunotherapeutics · 2024Article
- Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine.NPJ vaccines · 2022Article
- The transmembrane replacement H7N9-VLP vaccine displays high levels of protection in mice.Frontiers in microbiology · 2022Article
- Isoforms of the Papillomavirus Major Capsid Protein Differ in Their Ability to Block Viral Spread and Tumor Formation.Frontiers in immunology · 2022Article
- Expression of different L1 isoforms ofeLife · 2020Article
- A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects.EBioMedicine · 2016Article
- A Live Vector Expressing HPV16 L1 Generates an Adjuvant-Induced Antibody Response In-vivo.Iranian journal of cancer prevention · 2015Article
- Down-regulation of Frizzled-7 expression inhibits migration, invasion, and epithelial-mesenchymal transition of cervical cancer cell lines.Medical oncology (Northwood, London, England) · 2015Article
- A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice.Journal of translational medicine · 2015Article
- Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach.PloS one · 2015Article
- Human papillomaviruses-related cancers. Presence and prevention strategies in the Middle east and north African regions.Human vaccines & immunotherapeutics · 2014Review
- Ever closer to a prophylactic vaccine for HCV.Expert opinion on biological therapy · 2013Review
- Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease.Inflammatory bowel diseases · 2013Article
- Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.Virology journal · 2012Article
- Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.Advances in immunology · 2012Review
- New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention.Antiviral therapy · 2012Review
- Efficient production of HIV-1 virus-like particles from a mammalian expression vector requires the N-terminal capsid domain.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Oncogenic human papillomaviruses (HPVs) are exclusively mucosal pathogens that are noncytopathic and the basal epithelial cells harboring and maintaining an infection do not produce either capsid antigen or virus. The efficacy of the licensed L1 virus-like particle (VLP) vaccines has encouraged development of several second generation vaccines aimed at expanding the coverage to all oncogenic HPV types and reducing barriers to global implementation. Currently there is no defined immune correlate of protection that can be used to determine if an individual patient is protected and for the evaluation of these second generation vaccines. Surprisingly, passive transfer of neutralizing serum antibody is protective in animal models. Recent studies suggest how neutralizing antibody mediates immunity against mucosal HPV and the possible impact of memory B cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.